Abstract:Aim/Background: BSA dosing leads to great inter-individual DTX PK variability, which is a major contributor for severe toxicity, especially in East-Asian populations. DTX exposure measured by area under plasma concentration-time curve (AUC) could positively predict DTX related neutropenia. We conducted a randomized clinical trial to assess the value of PK-guided DTX dosing on relieving toxicity.Methods: To date, 99 Asian advanced NSCLC patients were randomly assigned to receive single agent 3-weekly DTX chemotherapy for up to 6 cycles, either at a fixed standard dose of 75 mg/m2 by BSA (arm1) or at a PK-guided dose (arm2) with a same starting dose. AUC is calculated from a published PK model. Dose of subsequent cycles of arm2 patients is calculated base on previous cycle, according to optimal AUC target (2.5–3.7 µg•h/mL) algorithm. Dose reductions were permitted in both arms for toxicities. The study had a power of 80% to detect a 23% reduction of grade >3 neutropenia with PK-guided arm.Results: Patients' major characteristics were male (62.6%), non-smoker (58.6%), ECOG 0 (80.8%) and adenocarcinoma (74.7%). 1st cycle of dosing 75 mg/m2 for all patients show 11 folds of PK variability, with mean AUC of 4.53 (range 1.8-20.3, CV = 56%), only 29.2% were in the target. Major patients (59.4%) were over exposed to DTX, experienced 18.5% higher of grade ≥3 neutropenia incidence. PK-guided dosing strategy could significantly reduce the dose of DTX, with a reduction of 8.6 mg/m2 (64.4 vs. 73.0, p < 0.001) in 2nd to 6th cycles. Patients therefore experienced 25.4% lower of grade ≥3 neutropenia incidence in PK-guided dose arm (47.5% vs. 72.9%, p = 0.002). Overall response rate showed no differences between arm2 and arm1 (20.0% vs. 17.5%, p = 0.769), so is progression free survival (4.6 vs. 3.4 months, p = 0.567).Conclusions: Majority of East-Asian NSCLC patients were over-exposed to DTX at a dose of 75 mg/m2. PK-guided dosing strategy could reduce DTX related neutropenia without efficacy damage.Clinical trial identification: NCT01891123Disclosure: All authors have declared no conflicts of interest. Aim/Background: BSA dosing leads to great inter-individual DTX PK variability, which is a major contributor for severe toxicity, especially in East-Asian populations. DTX exposure measured by area under plasma concentration-time curve (AUC) could positively predict DTX related neutropenia. We conducted a randomized clinical trial to assess the value of PK-guided DTX dosing on relieving toxicity. Methods: To date, 99 Asian advanced NSCLC patients were randomly assigned to receive single agent 3-weekly DTX chemotherapy for up to 6 cycles, either at a fixed standard dose of 75 mg/m2 by BSA (arm1) or at a PK-guided dose (arm2) with a same starting dose. AUC is calculated from a published PK model. Dose of subsequent cycles of arm2 patients is calculated base on previous cycle, according to optimal AUC target (2.5–3.7 µg•h/mL) algorithm. Dose reductions were permitted in both arms for toxicities. The study had a power of 80% to detect a 23% reduction of grade >3 neutropenia with PK-guided arm. Results: Patients' major characteristics were male (62.6%), non-smoker (58.6%), ECOG 0 (80.8%) and adenocarcinoma (74.7%). 1st cycle of dosing 75 mg/m2 for all patients show 11 folds of PK variability, with mean AUC of 4.53 (range 1.8-20.3, CV = 56%), only 29.2% were in the target. Major patients (59.4%) were over exposed to DTX, experienced 18.5% higher of grade ≥3 neutropenia incidence. PK-guided dosing strategy could significantly reduce the dose of DTX, with a reduction of 8.6 mg/m2 (64.4 vs. 73.0, p < 0.001) in 2nd to 6th cycles. Patients therefore experienced 25.4% lower of grade ≥3 neutropenia incidence in PK-guided dose arm (47.5% vs. 72.9%, p = 0.002). Overall response rate showed no differences between arm2 and arm1 (20.0% vs. 17.5%, p = 0.769), so is progression free survival (4.6 vs. 3.4 months, p = 0.567). Conclusions: Majority of East-Asian NSCLC patients were over-exposed to DTX at a dose of 75 mg/m2. PK-guided dosing strategy could reduce DTX related neutropenia without efficacy damage. Clinical trial identification: NCT01891123 Disclosure: All authors have declared no conflicts of interest.

Open-label Randomized Study of Individualized Pharmacokinetically (Pk)-Guided Dosing Versus Body Surface Area (BSA) Dosing of Paclitaxel (PTX) in Advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433

Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer.

Paclitaxel (ptx) Dose Individualization by Exposure Optimization in Chinese Patients with Advanced Non Small-Cell Lung Cancer (nsclc) Receiving First-Line Paclitaxel-Carboplatin (pc) Chemotherapy.

Outcome of Patients with a Performance Status of 2 in Eastern Cooperative Oncology Group Study E1594

424PD Individualization of docetaxel (DTX) treatment in East-Asian advanced non-small cell lung cancer (NSCLC) patients based on pharmacokinetically (PK)-guided dosing strategy: an open-label randomized clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

Randomized Controlled Comparative Clinical Pharmacokinetic Study of Nab-Paclitaxel and Solvent-Based Paclitaxel in Chinese Patients (pts) with Metastatic Breast Cancer (MBC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Randomized Study Comparing Nab-Paclitaxel With Solvent- Based Paclitaxel In Chinese Patients (Pts) With Metastatic Breast Cancer (Mbc)

A Retrospective Study in Chinese Patients: is There a Role of Nanoparticle Albumin Bound Paclitaxel in Advanced NSCLC?

Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients – a multicenter, randomized, comparative, phase II/III clinical study

Assessing the Clinical Outcome of Nab-Paclitaxel in Chinese Patients with Advanced Non-Small-cell Lung Cancer.

Paclitaxel Exposure-Toxicity Analysis Reveals a Pharmacokinetic Determinant for Dose-Limiting Neutropenia in East-Asian Solid Tumor Patients: Results from Two Prospective, Phase II Studies

Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors

A Dose-Finding Study of Nanoparticle Albumin-Bound Paclitaxel Plus Cisplatin in Patients with Metastatic Nasophyngeal Carcinomas.

Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-Based Paclitaxel As First-Line Treatment of Advanced Non-Small-cell Lung Cancer: an Open-Label, Randomized, Multicenter, Phase III Trial.

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

MA13.11 A Randomized Phase III Study of Cisplatin-Polymeric Micelle Paclitaxel vs Cisplatin-Solvent-Based Paclitaxel in 1st Line Advanced NSCLC